Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California; Kidney Health Research Collaborative with University of California, San Francisco VA Medical Center, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; Kidney Health Research Collaborative with University of California, San Francisco VA Medical Center, San Francisco, California; Department of Medicine, San Francisco VA Medical Center, San Francisco, California.
Am J Kidney Dis. 2022 Dec;80(6):762-772.e1. doi: 10.1053/j.ajkd.2022.05.011. Epub 2022 Jul 9.
RATIONALE & OBJECTIVE: Lower estimated glomerular filtration rate (eGFR) is associated with heart failure (HF) risk. However, eGFR based on cystatin C (eGFR) and creatinine (eGFR) may differ substantially within an individual. The clinical implications of these differences for risk of HF among persons with chronic kidney disease (CKD) are unknown.
Prospective cohort study.
SETTING & PARTICIPANTS: 4,512 adults with CKD and without prevalent HF who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study.
Difference in GFR estimates (eGFR; ie, eGFR minus eGFR).
Incident HF hospitalization.
Fine-Gray proportional subhazards regression was used to investigate the associations of baseline, time-updated, and slope of eGFR with incident HF.
Of 4,512 participants, one-third had eGFR and eGFR values that differed by over 15 mL/min/1.73 m. In multivariable-adjusted models, each 15 mL/min/1.73 m lower baseline eGFR was associated with higher risk of incident HF hospitalization (hazard ratio [HR], 1.20 [95% CI, 1.07-1.34]). In time-updated analyses, those with eGFR less than -15 mL/min/1.73 m had higher risk of incident HF hospitalization (HR, 1.99 [95% CI, 1.39-2.86]), and those with eGFR ≥15 mL/min/1.73 m had lower risk of incident HF hospitalization (HR, 0.67 [95% CI, 0.49-0.91]) compared with participants with similar eGFR and eGFR. Participants with faster declines in eGFR relative to eGFR had higher risk of incident HF (HR, 1.49 [95% CI, 1.19-1.85]) compared with those in whom eGFR and eGFR declined in parallel.
Entry into the CRIC Study was determined by eGFR, which constrained the range of baseline eGFR-but not eGFR-values.
Among persons with CKD who have large differences between eGFR and eGFR, risk for incident HF is more strongly associated with eGFR. Diverging slopes between eGFR and eGFR over time are also independently associated with risk of incident HF.
估算肾小球滤过率(eGFR)降低与心力衰竭(HF)风险相关。然而,基于半胱氨酸蛋白酶抑制剂(Cystatin C)的 eGFR(eGFR)和基于肌酐的 eGFR(eGFR)在个体内可能有很大差异。在慢性肾脏病(CKD)患者中,这些差异对 HF 风险的临床意义尚不清楚。
前瞻性队列研究。
4512 名患有 CKD 且无明显 HF 的成年人,他们参加了慢性肾功能不全队列(CRIC)研究。
GFR 估计值的差异(eGFR,即 eGFR 与 eGFR 之差)。
在 4512 名参与者中,有三分之一的人 eGFR 和 eGFR 值相差超过 15 mL/min/1.73 m。在多变量调整模型中,基线时每降低 15 mL/min/1.73 m 的 eGFR 与 HF 住院事件的发生风险更高相关(风险比 [HR],1.20 [95%CI,1.07-1.34])。在时间更新分析中,eGFR 低于-15 mL/min/1.73 m 的患者发生 HF 住院事件的风险更高(HR,1.99 [95%CI,1.39-2.86]),而 eGFR 高于 15 mL/min/1.73 m 的患者发生 HF 住院事件的风险更低(HR,0.67 [95%CI,0.49-0.91])与具有相似 eGFR 和 eGFR 的参与者相比。与 eGFR 和 eGFR 平行下降的患者相比,eGFR 相对于 eGFR 下降更快的患者发生 HF 的风险更高(HR,1.49 [95%CI,1.19-1.85])。
进入 CRIC 研究是由 eGFR 决定的,这限制了基线 eGFR 的范围,但不限制 eGFR 的范围。
在 eGFR 和 eGFR 差异较大的 CKD 患者中,发生 HF 的风险与 eGFR 更密切相关。随着时间的推移,eGFR 和 eGFR 之间的斜率差异也与 HF 事件的发生风险独立相关。